首页 > 最新文献

Allergology International最新文献

英文 中文
Black-box optimization in immunology and beyond: A practical guide to algorithms and future directions 黑箱优化在免疫学和超越:算法和未来方向的实用指南。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.08.006
Takanori Kawabata , Taku Tsuzuki , Tsuyoshi Tatsukawa , Kota Matsui , Eiryo Kawakami
The immune system presents some of the most complex challenges in biology, encompassing nonlinear interactions, high-dimensional regulatory mechanisms, and substantial variability across individuals and contexts. As a result, traditional model-driven approaches often fall short in optimizing experimental conditions or therapeutic strategies. Black-box optimization methods—particularly Bayesian optimization (BO) and evolutionary algorithms (EAs)—offer powerful tools for guiding biological discovery when mechanistic understanding is incomplete or intractable. These algorithms iteratively propose informative experiments by learning from noisy, expensive, and sparse data, enabling efficient exploration of vast experimental spaces. In this review, we provide a comprehensive overview of black-box optimization methodologies and their applications in life science, with a particular focus on immunology and allergy research. We detail how black-box optimization is transforming various stages of biomedical R&D, from molecular design (e.g., antibodies, peptides) and gene circuit tuning to culture protocol optimization and patient-specific dose adjustment. We highlight key algorithmic advances, including constrained, multi-objective, parallel and high-dimensional BO, as well as recent developments such as grey-box optimization and transfer learning. Practical considerations, such as software tools and reproducibility-enhancing checklists, are also discussed. By integrating black-box optimization with automated experimentation platforms and high-throughput biological systems, researchers can accelerate discovery, personalize interventions, and systematically optimize complex immunological processes. We argue that black-box optimization will become a foundational component of experimental design and decision-making in the life sciences, bridging computational strategies with biological insight in increasingly adaptive and interpretable ways.
免疫系统是生物学中一些最复杂的挑战,包括非线性相互作用,高维调节机制,以及个体和环境之间的巨大差异。因此,传统的模型驱动方法在优化实验条件或治疗策略方面往往存在不足。黑箱优化方法——尤其是贝叶斯优化(BO)和进化算法(ea)——在机制理解不完整或难以理解的情况下,为指导生物发现提供了强大的工具。这些算法通过从嘈杂、昂贵和稀疏的数据中学习,迭代地提出信息丰富的实验,从而能够有效地探索广阔的实验空间。本文综述了黑盒优化方法及其在生命科学中的应用,重点介绍了免疫学和过敏症研究。我们详细介绍了黑盒优化如何改变生物医学研发的各个阶段,从分子设计(例如,抗体,肽)和基因电路调整到培养方案优化和患者特异性剂量调整。我们强调了关键的算法进展,包括约束、多目标、并行和高维BO,以及最近的发展,如灰盒优化和迁移学习。还讨论了实际考虑因素,例如软件工具和增强再现性的检查表。通过将黑盒优化与自动化实验平台和高通量生物系统集成,研究人员可以加速发现,个性化干预,并系统地优化复杂的免疫过程。我们认为,黑箱优化将成为生命科学实验设计和决策的基础组成部分,以越来越适应和可解释的方式将计算策略与生物洞察力联系起来。
{"title":"Black-box optimization in immunology and beyond: A practical guide to algorithms and future directions","authors":"Takanori Kawabata ,&nbsp;Taku Tsuzuki ,&nbsp;Tsuyoshi Tatsukawa ,&nbsp;Kota Matsui ,&nbsp;Eiryo Kawakami","doi":"10.1016/j.alit.2025.08.006","DOIUrl":"10.1016/j.alit.2025.08.006","url":null,"abstract":"<div><div>The immune system presents some of the most complex challenges in biology, encompassing nonlinear interactions, high-dimensional regulatory mechanisms, and substantial variability across individuals and contexts. As a result, traditional model-driven approaches often fall short in optimizing experimental conditions or therapeutic strategies. Black-box optimization methods—particularly Bayesian optimization (BO) and evolutionary algorithms (EAs)—offer powerful tools for guiding biological discovery when mechanistic understanding is incomplete or intractable. These algorithms iteratively propose informative experiments by learning from noisy, expensive, and sparse data, enabling efficient exploration of vast experimental spaces. In this review, we provide a comprehensive overview of black-box optimization methodologies and their applications in life science, with a particular focus on immunology and allergy research. We detail how black-box optimization is transforming various stages of biomedical R&amp;D, from molecular design (e.g., antibodies, peptides) and gene circuit tuning to culture protocol optimization and patient-specific dose adjustment. We highlight key algorithmic advances, including constrained, multi-objective, parallel and high-dimensional BO, as well as recent developments such as grey-box optimization and transfer learning. Practical considerations, such as software tools and reproducibility-enhancing checklists, are also discussed. By integrating black-box optimization with automated experimentation platforms and high-throughput biological systems, researchers can accelerate discovery, personalize interventions, and systematically optimize complex immunological processes. We argue that black-box optimization will become a foundational component of experimental design and decision-making in the life sciences, bridging computational strategies with biological insight in increasingly adaptive and interpretable ways.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 549-562"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence and big data: Reshaping allergy research and patient care 人工智能和大数据:重塑过敏研究和患者护理
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.09.001
Eiryo Kawakami (Guest Editor, Allergology International)
{"title":"Artificial intelligence and big data: Reshaping allergy research and patient care","authors":"Eiryo Kawakami (Guest Editor, Allergology International)","doi":"10.1016/j.alit.2025.09.001","DOIUrl":"10.1016/j.alit.2025.09.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 497-498"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of GATA2 in the expression of the soluble decoy receptor ST2/IL1RL1 in human and mouse mast cells GATA2在人和小鼠肥大细胞中可溶性诱骗受体ST2/IL1RL1表达中的作用
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.04.004
Kazuki Nagata , Kazumi Kasakura , Kenta Ishii , Naoto Ito , Mutsuko Hara , Nobuhiro Nakano , Ko Okumura , Chiharu Nishiyama
{"title":"The role of GATA2 in the expression of the soluble decoy receptor ST2/IL1RL1 in human and mouse mast cells","authors":"Kazuki Nagata ,&nbsp;Kazumi Kasakura ,&nbsp;Kenta Ishii ,&nbsp;Naoto Ito ,&nbsp;Mutsuko Hara ,&nbsp;Nobuhiro Nakano ,&nbsp;Ko Okumura ,&nbsp;Chiharu Nishiyama","doi":"10.1016/j.alit.2025.04.004","DOIUrl":"10.1016/j.alit.2025.04.004","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 637-640"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Convergent monoclonal IgE antibodies from peanut allergic patients are multispecific to immunodominant epitopes of unrelated major peanut and tree nut allergens 来自花生过敏患者的收敛性单克隆IgE抗体对不相关的主要花生和树坚果过敏原的免疫显性表位具有多特异性。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.05.007
Stefan Kabasser , Tanja Kalic Kamath , Ernst Eber , Aleksandra Podzhilkova , Christian Lupinek , Wolfgang Hemmer , Mugdim Bublin , Derek Croote , Soheila J. Maleki , Heimo Breiteneder , Karin Hoffmann-Sommergruber , Christian Radauer , Merima Bublin

Background

Convergent selection has been identified in the IgE antibody repertoires of peanut-allergic individuals, primarily targeting the 2S albumin Ara h 2 and cross-reacting with two other major allergens, the vicilin Ara h 1 and the legumin Ara h 3. In this study, we aimed to investigate the structural and functional basis of this cross-reactivity and its contribution to the co-sensitization to tree nuts often observed in peanut-allergic subjects.

Methods

Six convergent antibodies, targeting the immunodominant Ara h 2-DPYSPS motif-associated sequence, and their reverted germline version, were produced as human IgG1 and IgE. Antibody specificity to natural and recombinant peanut and tree nut allergens and allergen-derived peptides was evaluated using ELISA, immunoblotting, inhibition tests, and basophil activation assays.

Results

The six antibodies showed reactivity to Ara h 1, Ara h 2, Ara h 3 and weak reactivity to tree nut legumins, especially from almond, walnut and Brazil nut. The germline antibody exclusively recognized Ara h 2. Basophils sensitized with the individual antibodies were activated by Ara h 2 at a concentration of 10 ng/ml and at 100-fold higher concentrations by Ara h 1 and Ara h 3, but not by tree nut legumins. The three Ara h 1- and two Ara h 3-derived antibody-binding peptides, with one from each group previously identified as immunodominant, are in close proximity and may contribute to conformational epitopes.

Conclusion

The biological activity of affinity-matured cross-reactive antibodies with Ara h 2-associated sequence convergence may explain the high allergenic potency of peanut and clinically irrelevant co-sensitizations to tree nuts commonly observed in peanut-allergic patients.
背景:在花生过敏个体的IgE抗体谱中发现了趋同选择,主要针对2S白蛋白Ara h2,并与另外两种主要过敏原,蛔虫蛋白Ara h1和豆类蛋白Ara h3交叉反应。在这项研究中,我们旨在研究这种交叉反应的结构和功能基础,以及它在花生过敏受试者中经常观察到的对树坚果的共致敏中的贡献。方法:制备6种针对Ara h 2-DPYSPS基序相关序列的趋同抗体,并将其还原为人IgG1和IgE。采用ELISA、免疫印迹、抑制试验和嗜碱性粒细胞活化试验评估对天然和重组花生和树坚果过敏原和过敏原衍生肽的抗体特异性。结果:6种抗体对arah1、arah2、arah3具有反应性,对树坚果类豆类蛋白的反应性较弱,尤其是杏仁、核桃和巴西坚果。种系抗体只识别Ara h2。被单个抗体致敏的嗜碱性细胞被浓度为10 ng/ml的Ara h2激活,Ara h1和Ara h3的浓度比Ara h2高100倍,但不被树坚果豆类蛋白激活。三个Ara h - 1和两个Ara h - 3衍生的抗体结合肽,每一组中有一个先前被确定为免疫优势,它们非常接近,可能有助于构象表位。结论:具有Ara h 2相关序列趋同的亲和成熟交叉反应抗体的生物学活性可能解释了花生高致敏效力和花生过敏患者常见的对树坚果的临床不相关的共致敏。
{"title":"Convergent monoclonal IgE antibodies from peanut allergic patients are multispecific to immunodominant epitopes of unrelated major peanut and tree nut allergens","authors":"Stefan Kabasser ,&nbsp;Tanja Kalic Kamath ,&nbsp;Ernst Eber ,&nbsp;Aleksandra Podzhilkova ,&nbsp;Christian Lupinek ,&nbsp;Wolfgang Hemmer ,&nbsp;Mugdim Bublin ,&nbsp;Derek Croote ,&nbsp;Soheila J. Maleki ,&nbsp;Heimo Breiteneder ,&nbsp;Karin Hoffmann-Sommergruber ,&nbsp;Christian Radauer ,&nbsp;Merima Bublin","doi":"10.1016/j.alit.2025.05.007","DOIUrl":"10.1016/j.alit.2025.05.007","url":null,"abstract":"<div><h3>Background</h3><div>Convergent selection has been identified in the IgE antibody repertoires of peanut-allergic individuals, primarily targeting the 2S albumin Ara h 2 and cross-reacting with two other major allergens, the vicilin Ara h 1 and the legumin Ara h 3. In this study, we aimed to investigate the structural and functional basis of this cross-reactivity and its contribution to the co-sensitization to tree nuts often observed in peanut-allergic subjects.</div></div><div><h3>Methods</h3><div>Six convergent antibodies, targeting the immunodominant Ara h 2-DPYSPS motif-associated sequence, and their reverted germline version, were produced as human IgG1 and IgE. Antibody specificity to natural and recombinant peanut and tree nut allergens and allergen-derived peptides was evaluated using ELISA, immunoblotting, inhibition tests, and basophil activation assays.</div></div><div><h3>Results</h3><div>The six antibodies showed reactivity to Ara h 1, Ara h 2, Ara h 3 and weak reactivity to tree nut legumins, especially from almond, walnut and Brazil nut. The germline antibody exclusively recognized Ara h 2. Basophils sensitized with the individual antibodies were activated by Ara h 2 at a concentration of 10 ng/ml and at 100-fold higher concentrations by Ara h 1 and Ara h 3, but not by tree nut legumins. The three Ara h 1- and two Ara h 3-derived antibody-binding peptides, with one from each group previously identified as immunodominant, are in close proximity and may contribute to conformational epitopes.</div></div><div><h3>Conclusion</h3><div>The biological activity of affinity-matured cross-reactive antibodies with Ara h 2-associated sequence convergence may explain the high allergenic potency of peanut and clinically irrelevant co-sensitizations to tree nuts commonly observed in peanut-allergic patients.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 622-632"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in clinical data analysis: A review of large language models, foundation models, digital twins, and allergy applications 临床数据分析中的人工智能:大型语言模型、基础模型、数字双胞胎和过敏应用综述。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.06.005
Yutaro Fuse , Shawn N. Murphy , Hisahiro Ikari , Akiko Takahashi , Kenshiro Fuse , Eiryo Kawakami
Recent advances in computing technology and the development of data utilization environments have rapidly accelerated the application of artificial intelligence in clinical research and healthcare. This review provides a comprehensive overview of current machine learning techniques for analyzing clinical data, with illustrative examples from the field of allergic diseases. In addition to conventional methods for clinical data analysis, we discuss emerging approaches including medical image analysis and time-series modeling of electronic health record data. Recent developments such as large language models and foundation models trained on massive datasets are also discussed. Looking ahead, we explore future directions in analytical methodology, including mathematical modeling, interpretable artificial intelligence, and multimodal learning that integrates various data types. We also introduce the concept of the digital twin—a virtual representation of an individual patient that simulates disease progression and treatment response—as a promising concept for advancing precision medicine. Finally, we discuss the essential role of physicians in the development and implementation of machine learning tools and discuss emerging ethical issues such as fairness, privacy, and patient autonomy. By synthesizing recent technical advances with clinical relevance, this review aims to provide clinicians and researchers with a practical and forward-looking guide to machine learning in clinical medicine, including its growing application in the field of allergy.
最近计算技术的进步和数据利用环境的发展迅速加速了人工智能在临床研究和医疗保健中的应用。本文综述了当前用于分析临床数据的机器学习技术的全面概述,并提供了过敏性疾病领域的说明性示例。除了传统的临床数据分析方法外,我们还讨论了新兴的方法,包括医学图像分析和电子健康记录数据的时间序列建模。最近的发展,如大型语言模型和基础模型训练的大规模数据集也进行了讨论。展望未来,我们将探索分析方法的未来方向,包括数学建模、可解释的人工智能和集成各种数据类型的多模态学习。我们还介绍了数字孪生的概念——模拟疾病进展和治疗反应的单个患者的虚拟表示——作为推进精准医学的一个有前途的概念。最后,我们讨论了医生在机器学习工具的开发和实施中的重要作用,并讨论了诸如公平、隐私和患者自主权等新兴伦理问题。通过综合近期与临床相关的技术进展,本综述旨在为临床医生和研究人员提供实用和前瞻性的临床医学机器学习指南,包括其在过敏领域的日益增长的应用。
{"title":"Artificial intelligence in clinical data analysis: A review of large language models, foundation models, digital twins, and allergy applications","authors":"Yutaro Fuse ,&nbsp;Shawn N. Murphy ,&nbsp;Hisahiro Ikari ,&nbsp;Akiko Takahashi ,&nbsp;Kenshiro Fuse ,&nbsp;Eiryo Kawakami","doi":"10.1016/j.alit.2025.06.005","DOIUrl":"10.1016/j.alit.2025.06.005","url":null,"abstract":"<div><div>Recent advances in computing technology and the development of data utilization environments have rapidly accelerated the application of artificial intelligence in clinical research and healthcare. This review provides a comprehensive overview of current machine learning techniques for analyzing clinical data, with illustrative examples from the field of allergic diseases. In addition to conventional methods for clinical data analysis, we discuss emerging approaches including medical image analysis and time-series modeling of electronic health record data. Recent developments such as large language models and foundation models trained on massive datasets are also discussed. Looking ahead, we explore future directions in analytical methodology, including mathematical modeling, interpretable artificial intelligence, and multimodal learning that integrates various data types. We also introduce the concept of the digital twin—a virtual representation of an individual patient that simulates disease progression and treatment response—as a promising concept for advancing precision medicine. Finally, we discuss the essential role of physicians in the development and implementation of machine learning tools and discuss emerging ethical issues such as fairness, privacy, and patient autonomy. By synthesizing recent technical advances with clinical relevance, this review aims to provide clinicians and researchers with a practical and forward-looking guide to machine learning in clinical medicine, including its growing application in the field of allergy.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 499-513"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing 一种用于功能分析和体外过敏试验的新型人嗜碱性细胞系的建立。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.03.003
Ryo Kurita, Takaaki Abe, Kanako Maebara, Daisuke Takahashi, Shigeki Miyata, Masahiro Satake, Yoshihiko Tani

Background

Basophils are the rarest granulocytes and play diverse roles, e.g., in protective immunity and allergic inflammatory reactions. However, the underlying molecules and mechanisms involved in basophil differentiation and functions, particularly in humans, remain largely unknown. This may be due to the lack of high-quality research tools.

Methods

We established a novel, immortalized, human basophil cell line by introducing human papillomavirus 16-E6/E7, c-MYC, and BCL-xL gene expression systems into cultured basophils, and evaluated whether this cell line is useful as a research tool, compared with KU812, which is the most commonly-used human basophil cell line.

Results

This cell line expressed various basophil markers, including CD123, CD203c, and the high-affinity immunoglobulin (Ig)E receptor α-chain and can mature into more differentiated cells under specific culture conditions. The differentiated cells stimulated with anti-IgE antibodies showed increased CD203c expression in a dose-dependent manner, whereas the differentiated KU812 cells showed little activation after the stimulation.
The established cell line also demonstrated increased sensitivity to allergic activation when stimulated with an allergen (NP-BSA) and allergen-specific IgE (anti-NP-IgE). Furthermore, histamine- and interleukin-4-releasing abilities were also confirmed. These allergic activation profiles were similar to those of basophils from healthy individuals, although the activation levels of the established cells were lower than those of basophils from highly-sensitive individuals.

Conclusions

These findings suggest that the established basophil cell line has substantially different characteristics from a conventional cell line and could serve as a new tool for investigating basophil differentiation and functions, as well as for testing allergic reactions.
背景:嗜碱性粒细胞是最罕见的粒细胞,在保护性免疫和过敏性炎症反应中发挥着多种作用。然而,涉及嗜碱性粒细胞分化和功能的潜在分子和机制,特别是在人类中,仍然很大程度上未知。这可能是由于缺乏高质量的研究工具。方法:将人乳头瘤病毒16-E6/E7、c-MYC和BCL-xL基因表达系统导入培养的嗜碱性细胞中,建立一种新的永生化人嗜碱性细胞系,并与最常用的人嗜碱性细胞系KU812进行比较,评估该细胞系是否可作为研究工具。结果:该细胞系表达CD123、CD203c及高亲和性免疫球蛋白E受体α-链等多种嗜碱性细胞标志物,在特定培养条件下可成熟为分化程度较高的细胞。经抗ige抗体刺激的分化细胞CD203c表达呈剂量依赖性增加,而KU812细胞在刺激后几乎没有活化。当用过敏原(NP-BSA)和过敏原特异性IgE(抗np -IgE)刺激时,所建立的细胞系也显示出对过敏激活的敏感性增加。此外,组胺和白细胞介素-4的释放能力也得到证实。这些过敏激活谱与来自健康个体的嗜碱性细胞相似,尽管建立的细胞的激活水平低于来自高度敏感个体的嗜碱性细胞。结论:这些发现表明,所建立的嗜碱性粒细胞细胞系具有与常规细胞系截然不同的特征,可以作为研究嗜碱性粒细胞分化和功能以及检测过敏反应的新工具。
{"title":"Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing","authors":"Ryo Kurita,&nbsp;Takaaki Abe,&nbsp;Kanako Maebara,&nbsp;Daisuke Takahashi,&nbsp;Shigeki Miyata,&nbsp;Masahiro Satake,&nbsp;Yoshihiko Tani","doi":"10.1016/j.alit.2025.03.003","DOIUrl":"10.1016/j.alit.2025.03.003","url":null,"abstract":"<div><h3>Background</h3><div>Basophils are the rarest granulocytes and play diverse roles, e.g., in protective immunity and allergic inflammatory reactions. However, the underlying molecules and mechanisms involved in basophil differentiation and functions, particularly in humans, remain largely unknown. This may be due to the lack of high-quality research tools.</div></div><div><h3>Methods</h3><div>We established a novel, immortalized, human basophil cell line by introducing human papillomavirus 16-E6<em>/</em>E7, <em>c-MYC</em>, and <em>BCL-xL</em> gene expression systems into cultured basophils, and evaluated whether this cell line is useful as a research tool, compared with KU812, which is the most commonly-used human basophil cell line.</div></div><div><h3>Results</h3><div>This cell line expressed various basophil markers, including CD123, CD203c, and the high-affinity immunoglobulin (Ig)E receptor α-chain and can mature into more differentiated cells under specific culture conditions. The differentiated cells stimulated with anti-IgE antibodies showed increased CD203c expression in a dose-dependent manner, whereas the differentiated KU812 cells showed little activation after the stimulation.</div><div>The established cell line also demonstrated increased sensitivity to allergic activation when stimulated with an allergen (NP-BSA) and allergen-specific IgE (anti-NP-IgE). Furthermore, histamine- and interleukin-4-releasing abilities were also confirmed. These allergic activation profiles were similar to those of basophils from healthy individuals, although the activation levels of the established cells were lower than those of basophils from highly-sensitive individuals.</div></div><div><h3>Conclusions</h3><div>These findings suggest that the established basophil cell line has substantially different characteristics from a conventional cell line and could serve as a new tool for investigating basophil differentiation and functions, as well as for testing allergic reactions.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 579-590"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement of atopic dermatitis-like symptoms in a murine model via the chromogranin A-derived peptide catestatin 通过嗜铬粒蛋白a衍生肽catestatin改善小鼠模型中的特应性皮炎样症状。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.01.001
Ge Peng , Wanchen Zhao , Alafate Abudouwanli , Quan Sun , Mengyao Yang , Shan Wang , Yi Tan , Arisa Ikeda , Shigaku Ikeda , Hideoki Ogawa , Ko Okumura , François Niyonsaba

Background

Atopic dermatitis (AD), a prevalent chronic inflammatory skin disorder, is characterized by compromised skin barrier and heightened immune responses. The study investigates the therapeutic efficacy of catestatin (CST), a chromogranin A-derived antimicrobial peptide, in mitigating AD-like symptoms.

Methods

Utilizing both keratinocyte cultures and a C57BL/6 mouse model, we examined CST's impact on skin barrier proteins, tight junction (TJ) integrity, inflammatory cytokines, and AD-like symptoms.

Results

CST administration led to a significant upregulation of skin barrier proteins and improved TJ function, counteracting the negative effects of Th2 cytokines on these parameters. In a 2,4-dinitrochlorobenzene-induced AD mouse model, CST treatment markedly reduced AD-like symptoms, including ear thickness, transepidermal water loss, and scratching behavior, and normalized barrier protein expression and TJ barrier function. Furthermore, CST was found to interact with the Notch1 receptor, activating the Notch1/PKC pathway, which may underlie its skin barrier-enhancing properties.

Conclusions

Collectively, these findings suggest CST as a promising therapeutic agent for AD, capable of enhancing skin barrier function, modulating immune responses, and targeting the Notch1/PKC pathway, offering a novel approach to AD treatment focusing on barrier restoration and immune modulation.
背景:特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,其特征是皮肤屏障受损和免疫反应增强。该研究调查了catestatin (CST)的治疗效果,catestatin是一种铬粒蛋白a衍生的抗菌肽,可缓解ad样症状。方法:利用角化细胞培养和C57BL/6小鼠模型,研究了CST对皮肤屏障蛋白、紧密连接(TJ)完整性、炎症细胞因子和ad样症状的影响。结果:CST可显著上调皮肤屏障蛋白,改善TJ功能,抵消Th2细胞因子对这些参数的负面影响。在2,4-二硝基氯苯诱导的AD小鼠模型中,CST治疗显著减少AD样症状,包括耳厚、经皮失水和抓伤行为,并使屏障蛋白表达和TJ屏障功能正常化。此外,CST被发现与Notch1受体相互作用,激活Notch1/PKC通路,这可能是其皮肤屏障增强特性的基础。综上所述,这些发现表明CST是一种很有前景的AD治疗药物,能够增强皮肤屏障功能,调节免疫反应,并靶向Notch1/PKC通路,为AD治疗提供了一种新的途径,重点是屏障恢复和免疫调节。
{"title":"Improvement of atopic dermatitis-like symptoms in a murine model via the chromogranin A-derived peptide catestatin","authors":"Ge Peng ,&nbsp;Wanchen Zhao ,&nbsp;Alafate Abudouwanli ,&nbsp;Quan Sun ,&nbsp;Mengyao Yang ,&nbsp;Shan Wang ,&nbsp;Yi Tan ,&nbsp;Arisa Ikeda ,&nbsp;Shigaku Ikeda ,&nbsp;Hideoki Ogawa ,&nbsp;Ko Okumura ,&nbsp;François Niyonsaba","doi":"10.1016/j.alit.2025.01.001","DOIUrl":"10.1016/j.alit.2025.01.001","url":null,"abstract":"<div><h3>Background</h3><div>Atopic dermatitis (AD), a prevalent chronic inflammatory skin disorder, is characterized by compromised skin barrier and heightened immune responses. The study investigates the therapeutic efficacy of catestatin (CST), a chromogranin A-derived antimicrobial peptide, in mitigating AD-like symptoms.</div></div><div><h3>Methods</h3><div>Utilizing both keratinocyte cultures and a C57BL/6 mouse model, we examined CST's impact on skin barrier proteins, tight junction (TJ) integrity, inflammatory cytokines, and AD-like symptoms.</div></div><div><h3>Results</h3><div>CST administration led to a significant upregulation of skin barrier proteins and improved TJ function, counteracting the negative effects of Th2 cytokines on these parameters. In a 2,4-dinitrochlorobenzene-induced AD mouse model, CST treatment markedly reduced AD-like symptoms, including ear thickness, transepidermal water loss, and scratching behavior, and normalized barrier protein expression and TJ barrier function. Furthermore, CST was found to interact with the Notch1 receptor, activating the Notch1/PKC pathway, which may underlie its skin barrier-enhancing properties.</div></div><div><h3>Conclusions</h3><div>Collectively, these findings suggest CST as a promising therapeutic agent for AD, capable of enhancing skin barrier function, modulating immune responses, and targeting the Notch1/PKC pathway, offering a novel approach to AD treatment focusing on barrier restoration and immune modulation.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 563-571"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative omics redefining allergy mechanisms and precision medicine 综合组学重新定义过敏机制和精准医学。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.08.007
Ayano Fukushima-Nomura , Hiroshi Kawasaki , Masayuki Amagai
Allergic diseases are characterized by heterogeneity driven by complex interactions between genetic, environmental, and immunological factors. Conventional classifications based solely on clinical phenotypes often fails to capture the underlying molecular diversity, thereby limiting therapeutic precision and patient outcomes. Integrative omics—encompassing genomics, transcriptomics, proteomics, metabolomics, and microbiomics—has emerged as a powerful approach to redefine disease mechanisms and advance precision medicine. By integrating high-dimensional molecular data with clinical phenotyping, omics approaches enable the identification of disease endotypes, biomarker discovery, and patient stratification.
This review highlights recent developments in clinical-omics integration, with a focus on atopic dermatitis (AD) as a prototypical allergic disease. Drawing from our studies, we illustrate how tissue-level transcriptomic profiling, combined with unbiased computational analysis, can uncover immunological heterogeneity and treatment-response patterns in AD. Additional examples in asthma and food allergy demonstrate how integrated multi-omics can uncover gene-environment interactions and elucidate mechanisms behind disease severity and health disparities.
We also address practical and ethical challenges in data harmonization, privacy, and interoperability, and underscore the critical role of computational methods and infrastructure development in enabling clinically meaningful interpretation. Importantly, successful translation of multi-omics data into clinical practice requires iterative, interdisciplinary collaboration between clinicians, data scientists, and basic researchers.
By bridging molecular complexity and clinical heterogeneity, integrative omics is reshaping the landscape of allergy research. As technologies evolve, this framework will be crucial for developing predictive models and personalized therapeutic strategies, ultimately bringing us closer to individualized, data-driven care in allergic diseases.
变应性疾病的特点是由遗传、环境和免疫因素之间复杂的相互作用驱动的异质性。仅基于临床表型的传统分类往往无法捕获潜在的分子多样性,从而限制了治疗精度和患者结果。整合组学——包括基因组学、转录组学、蛋白质组学、代谢组学和微生物组学——已经成为重新定义疾病机制和推进精准医学的有力方法。通过将高维分子数据与临床表型相结合,组学方法能够识别疾病内型、发现生物标志物和患者分层。本文综述了临床-组学整合的最新进展,重点关注特应性皮炎(AD)作为一种典型的过敏性疾病。根据我们的研究,我们说明了组织水平的转录组学分析,结合无偏倚的计算分析,如何揭示AD的免疫异质性和治疗反应模式。哮喘和食物过敏的其他例子表明,综合多组学可以揭示基因与环境的相互作用,并阐明疾病严重程度和健康差异背后的机制。我们还解决了数据协调、隐私和互操作性方面的实际和伦理挑战,并强调了计算方法和基础设施发展在实现临床有意义的解释方面的关键作用。重要的是,将多组学数据成功转化为临床实践需要临床医生、数据科学家和基础研究人员之间反复的跨学科合作。通过桥接分子复杂性和临床异质性,整合组学正在重塑过敏研究的景观。随着技术的发展,这一框架将对开发预测模型和个性化治疗策略至关重要,最终使我们更接近个性化、数据驱动的过敏性疾病护理。
{"title":"Integrative omics redefining allergy mechanisms and precision medicine","authors":"Ayano Fukushima-Nomura ,&nbsp;Hiroshi Kawasaki ,&nbsp;Masayuki Amagai","doi":"10.1016/j.alit.2025.08.007","DOIUrl":"10.1016/j.alit.2025.08.007","url":null,"abstract":"<div><div>Allergic diseases are characterized by heterogeneity driven by complex interactions between genetic, environmental, and immunological factors. Conventional classifications based solely on clinical phenotypes often fails to capture the underlying molecular diversity, thereby limiting therapeutic precision and patient outcomes. Integrative omics—encompassing genomics, transcriptomics, proteomics, metabolomics, and microbiomics—has emerged as a powerful approach to redefine disease mechanisms and advance precision medicine. By integrating high-dimensional molecular data with clinical phenotyping, omics approaches enable the identification of disease endotypes, biomarker discovery, and patient stratification.</div><div>This review highlights recent developments in clinical-omics integration, with a focus on atopic dermatitis (AD) as a prototypical allergic disease. Drawing from our studies, we illustrate how tissue-level transcriptomic profiling, combined with unbiased computational analysis, can uncover immunological heterogeneity and treatment-response patterns in AD. Additional examples in asthma and food allergy demonstrate how integrated multi-omics can uncover gene-environment interactions and elucidate mechanisms behind disease severity and health disparities.</div><div>We also address practical and ethical challenges in data harmonization, privacy, and interoperability, and underscore the critical role of computational methods and infrastructure development in enabling clinically meaningful interpretation. Importantly, successful translation of multi-omics data into clinical practice requires iterative, interdisciplinary collaboration between clinicians, data scientists, and basic researchers.</div><div>By bridging molecular complexity and clinical heterogeneity, integrative omics is reshaping the landscape of allergy research. As technologies evolve, this framework will be crucial for developing predictive models and personalized therapeutic strategies, ultimately bringing us closer to individualized, data-driven care in allergic diseases.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 514-524"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exacerbated signs of atopic dermatitis with gut dysbiosis predominate in male than in female adult patients 伴有肠道生态失调的特应性皮炎症状加重的男性成人患者多于女性成人患者。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.04.002
Susumu Ichiyama , Kozo Ohkusu-Tsukada , Hidehisa Saeki
{"title":"Exacerbated signs of atopic dermatitis with gut dysbiosis predominate in male than in female adult patients","authors":"Susumu Ichiyama ,&nbsp;Kozo Ohkusu-Tsukada ,&nbsp;Hidehisa Saeki","doi":"10.1016/j.alit.2025.04.002","DOIUrl":"10.1016/j.alit.2025.04.002","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 633-636"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients 中性粒细胞作为表达il1b的细胞在Schnitzler综合征中占主导地位:来自SCan研究的见解,以评估canakinumab在日本患者中的有效性和安全性。
IF 6.7 2区 医学 Q1 ALLERGY Pub Date : 2025-10-01 DOI: 10.1016/j.alit.2025.04.003
Naotomo Kambe , Norimitsu Inoue , Yoko Ueki , Yuyi Zhou , Satoru Yonekura , Kosuke Katsuo , Satoshi Nakamizo , Hiroshi Tsujimoto , Katsuki Ohtani , Hajime Yoshifuji , Tomoyasu Jo , Kazushi Izawa , Mayuko Yamamoto , Koji Takemura , Shin-ichiro Kagami , Yoshie Kawahara , Yoko Amino , Yumiko Ibi , Satoshi Morita , Nobuo Kanazawa

Background

Schnitzler syndrome (SchS) is a late-onset autoinflammatory disease characterized by urticarial rash and monoclonal gammopathy. SchS shares clinical features with cryopyrin-associated periodic syndrome, which is driven by gain-of-function mutations in NLRP3, and while IL-1β-targeted therapies have shown efficacy, the underlying pathogenesis of SchS remains unclear.

Methods

During a multicenter, single-arm, open-label, investigator-initiated trial evaluating the efficacy and safety of canakinumab in five Japanese patients with SchS (named the SCan Study after SchS and Canakinumab), based on a similar study conducted in Germany, we measured 32 cytokines/chemokines and 11 complement-related factors in plasma and analyzed their correlations with changes in clinical symptoms during treatment. Furthermore, in two cases, single-cell RNA sequencing of peripheral blood and spatial transcriptomic analysis of lesional skin were performed to identify IL1B-expressing cells.

Results

The improvement in clinical symptoms and quality of life was maintained for 48 weeks following canakinumab treatment. Notably, these changes in clinical symptoms strongly correlated with WBC count, neutrophil count, CRP, and serum amyloid A levels, which were used as evaluation parameters in this study. In contrast, IL-1β and most other cytokines/chemokines exhibited distinct patterns and were not useful as markers of disease activity. IgM levels remained stable without an upward trend. Additionally, IL1B-expressing cells were predominantly neutrophils in both peripheral blood and lesional skin. Furthermore, neutrophil counts in peripheral blood decreased following canakinumab administration.

Conclusions

This study demonstrated that the primary source of IL1B-expressing cells in SchS is neutrophils. Moreover, canakinumab improves clinical symptoms by regulating neutrophil dynamics in peripheral blood.
背景:Schnitzler综合征(SchS)是一种以荨麻疹和单克隆γ病为特征的迟发性自身炎症性疾病。SchS与cryopyrin相关周期性综合征具有相同的临床特征,后者是由NLRP3的功能获得性突变驱动的,尽管il -1β靶向治疗已显示出疗效,但SchS的潜在发病机制尚不清楚。方法:在一项多中心、单组、开放标签、研究者发起的试验中,评估了canakinumab对5名日本SchS患者的疗效和安全性(以SchS和canakinumab命名的SCan研究),基于德国的一项类似研究,我们测量了血浆中的32种细胞因子/趋化因子和11种补体相关因子,并分析了它们与治疗期间临床症状变化的相关性。此外,在两个病例中,通过外周血单细胞RNA测序和病变皮肤的空间转录组分析来鉴定表达il1b的细胞。结果:canakinumab治疗后临床症状和生活质量的改善维持了48周。值得注意的是,这些临床症状的变化与WBC计数、中性粒细胞计数、CRP和血清淀粉样蛋白A水平密切相关,这些是本研究的评估参数。相比之下,IL-1β和大多数其他细胞因子/趋化因子表现出不同的模式,不能作为疾病活动的标志物。IgM水平保持稳定,没有上升趋势。此外,外周血和病变皮肤中表达il1b的细胞主要是中性粒细胞。此外,canakinumab给药后,外周血中性粒细胞计数下降。结论:本研究表明,SchS中il1b表达细胞的主要来源是中性粒细胞。此外,canakinumab通过调节外周血中性粒细胞动力学改善临床症状。
{"title":"Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients","authors":"Naotomo Kambe ,&nbsp;Norimitsu Inoue ,&nbsp;Yoko Ueki ,&nbsp;Yuyi Zhou ,&nbsp;Satoru Yonekura ,&nbsp;Kosuke Katsuo ,&nbsp;Satoshi Nakamizo ,&nbsp;Hiroshi Tsujimoto ,&nbsp;Katsuki Ohtani ,&nbsp;Hajime Yoshifuji ,&nbsp;Tomoyasu Jo ,&nbsp;Kazushi Izawa ,&nbsp;Mayuko Yamamoto ,&nbsp;Koji Takemura ,&nbsp;Shin-ichiro Kagami ,&nbsp;Yoshie Kawahara ,&nbsp;Yoko Amino ,&nbsp;Yumiko Ibi ,&nbsp;Satoshi Morita ,&nbsp;Nobuo Kanazawa","doi":"10.1016/j.alit.2025.04.003","DOIUrl":"10.1016/j.alit.2025.04.003","url":null,"abstract":"<div><h3>Background</h3><div>Schnitzler syndrome (SchS) is a late-onset autoinflammatory disease characterized by urticarial rash and monoclonal gammopathy. SchS shares clinical features with cryopyrin-associated periodic syndrome, which is driven by gain-of-function mutations in <em>NLRP3</em>, and while IL-1β-targeted therapies have shown efficacy, the underlying pathogenesis of SchS remains unclear.</div></div><div><h3>Methods</h3><div>During a multicenter, single-arm, open-label, investigator-initiated trial evaluating the efficacy and safety of canakinumab in five Japanese patients with SchS (named the SCan Study after SchS and Canakinumab), based on a similar study conducted in Germany, we measured 32 cytokines/chemokines and 11 complement-related factors in plasma and analyzed their correlations with changes in clinical symptoms during treatment. Furthermore, in two cases, single-cell RNA sequencing of peripheral blood and spatial transcriptomic analysis of lesional skin were performed to identify <em>IL1B</em>-expressing cells.</div></div><div><h3>Results</h3><div>The improvement in clinical symptoms and quality of life was maintained for 48 weeks following canakinumab treatment. Notably, these changes in clinical symptoms strongly correlated with WBC count, neutrophil count, CRP, and serum amyloid A levels, which were used as evaluation parameters in this study. In contrast, IL-1β and most other cytokines/chemokines exhibited distinct patterns and were not useful as markers of disease activity. IgM levels remained stable without an upward trend. Additionally, <em>IL1B</em>-expressing cells were predominantly neutrophils in both peripheral blood and lesional skin. Furthermore, neutrophil counts in peripheral blood decreased following canakinumab administration.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that the primary source of <em>IL1B-</em>expressing cells in SchS is neutrophils. Moreover, canakinumab improves clinical symptoms by regulating neutrophil dynamics in peripheral blood.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 605-615"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergology International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1